Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Intensive Temozolomide in Elderly Glioblastoma
NCT00365222Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Jul 2006
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in glioblastoma (GBM), sponsored by Moffitt Cancer Center. Primary endpoint: Overall Survival. Started Jul 2006; status: terminated.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00365222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365222.